NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Medical Devices · USD

Xtant Medical Holdings, Inc. (XTNT) Stock Analysis

Xtant Medical Holdings, Inc. (XTNT) is a Medical Devices stock listed on NYSE American and quoted in US Dollar.

XTNT

$0.38

−$0.02 (−5.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XTNT with… →

XTNT Key Statistics

As of Sep 4, 2026
Trading
Open
$0.39
Previous Close
$0.40
Day's Range
0.37–0.40
52-Week Range
0.27–0.95
Volume
379.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.15
Valuation
Market Cap
$52.61M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.74
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.48
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.08
Financials (FY)
Revenue (FY)
$133.93M+14.21%
Net Income (FY)
$4.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.17%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
140.29M
1-Year Return
−37.70%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
1.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XTNT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−51.28%
2025+77.27%
2024−61.06%
2023+71.21%
2022+17.86%
2021−53.33%
2020−25.00%
2019−0.62%
2018−76.46%
2017+3.64%
2016 (partial year)−68.57%

As of September 4, 2026.

XTNT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$133.93M$4.97M3.7%
2024$117.27M−$16.45M−14.0%
2023$91.30M$660.00K0.7%
2022$57.97M−$8.49M−14.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$133.93M$84.27M$7.28M$4.97M3.7%
2024$117.27M$68.22M−$12.07M−$16.45M−14.0%
2023$91.30M$55.47M−$10.16M$660.00K0.7%
2022$57.97M$32.14M−$6.76M−$8.49M−14.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XTNT Valuation vs Medical Devices Median

Median of 151 stocks
MetricXTNTMedical Devices medianvs median
P/S ratio0.482.980.2x the median
Profit margin−10.17%−1.69%8.5 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xtant Medical Holdings, Inc. (XTNT) carries a market capitalisation of $52.61M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 151.

The most recent close on file for XTNT is $0.38, dated September 4, 2026. That is −$0.02 (−5.00%) against the previous close. Over the past 52 weeks the price has ranged from $0.27 to $0.95. The latest close sits 40.74% above that 52-week low.

Financial Health

In fiscal 2025, Xtant Medical Holdings, Inc. reported revenue of $133.93M. Against the prior fiscal year total of $117.27M, that is a change of +14.21%. Net income for the same year was $4.97M. Profit margin runs at −10.17%. That is 8.5 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.08.

Across the 4 fiscal years on file, revenue moves from $57.97M in 2022 to $133.93M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.74. Measured against sales, the shares trade at 0.48 times revenue. On price-to-sales that is 0.2 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −37.70%. Measured over 10 years, that is −31.24% a year compounded. The reported beta is −0.15. Annualized volatility over the trailing 10 years is 113.44%.

Growth & Income

No dividend is on file for XTNT.

Across the complete calendar years on file, 2025 returned +77.27% and 2018 returned −76.46%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −51.28% year to date.

Peer Comparison

Xtant Medical Holdings, Inc. (XTNT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xtant Medical Holdings, Inc. XTNT $52.61M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Xtant Medical Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Visit website →